Effects of maternal caffeine consumption on the breastfed child : a systematic review by McCreedy, Aimee et al.
Systematic review | Published 28 September 2018 | doi:10.4414/smw.2018.14665
Cite this as: Swiss Med Wkly. 2018;148:w14665
Effects of maternal caffeine consumption on the
breastfed child: a systematic review
McCreedy Aimeea, Bird Sumedhab, Brown Lucy J.a, Shaw-Stewart Jamesa, Chen Yen-Fua
a University of Warwick, Coventry, United Kingdom
b South Warwickshire NHS Foundation Trust, Warwick, United Kingdom
Summary
BACKGROUND: Nutrition in the first 1000 days between
pregnancy and 24 months of life is critical for child health,
and exclusive breastfeeding is promoted as the infant’s
best source of nutrition in the first 6 months. Caffeine is
a central nervous system stimulant occurring naturally in
some foods and used to treat primary apnoea in prema-
ture babies. However high caffeine intake can be harmful,
and caffeine is transmitted into breastmilk.
AIM: To systematically review the evidence on the effects
of maternal caffeine consumption during breastfeeding on
the breastfed child.
: METHOD: A systematic search was conducted to Oc-
tober 2017 in MEDLINE, EMBASE, Web of Science,
CINAHL, and Cochrane Library. The British Library cata-
logue, which covers doctoral theses, was searched and
PRISMA guidelines followed. Two reviewers screened for
experimental, cohort, or case-control studies and per-
formed independent quality assessment using the New-
castle-Ottawa scale. The main reviewer performed data
extraction, checked by the second reviewer.
RESULTS: Two cohort, two crossover studies, and one
N-of-1 trial were included for narrative synthesis. One
crossover and two cohort studies of small sample sizes di-
rectly investigated maternal caffeine consumption. No sig-
nificant effects on 24-hour heart rate, 24-hour sleep time,
or frequent night waking of the breastfed child were found.
One study found a decreased rate of full breastfeeding
at 6 months postpartum. Two studies indirectly investigat-
ed caffeine exposure. Maternal chocolate and coffee con-
sumption was associated with increased infant colic, and
severe to moderate exacerbation of infant atopic dermati-
tis. However, whether caffeine was the causal ingredient
is questionable. The insufficient and inconsistent evidence
available had quality issues impeding conclusions on the
effects of maternal caffeine consumption on the breastfed
child.
CONCLUSION: Evidence for recommendations on caf-
feine intake for breastfeeding women is scant, of limited
quality and inconclusive. Birth cohort studies investigating
the potential positive and negative effects of various levels
of maternal caffeine consumption on the breastfed child
and breastfeeding mother could improve the knowledge
base and allow evidence-based advice for breastfeeding
mothers.
Systematic review registration number:
CRD42017078790
Keywords: caffeine, breastfeeding, coffee, maternal out-
comes, infant outcomes, maternal and child health, lacta-
tion, nutrition, systematic review
Background
It is widely acknowledged that the first 1000 days from
pregnancy to a child’s second birthday is “the crucial win-
dow of opportunity” for delivery of nutrition to children,
potentially impacting on a child’s current and adult health,
and the health of subsequent generations ([1] p.1). Exclu-
sive breastfeeding is promoted as the infant’s best first
source of nutrition and the World Health Organization rec-
ommends that infants are exclusively breastfed for at least
6 months stating “with full confidence that breastfeeding
reduces child mortality and has health benefits that extend
into adulthood” ([2] para.1).
To promote health in the infant and mother, breastfeeding
women are advised to make alterations to their diet, in-
cluding recommendations about caffeine intake. For ex-
ample, the European Food Safety Authority suggests that
“habitual caffeine consumption at doses of 200 mg per
day consumed by lactating women in the general popula-
tion do not give rise to safety concerns for the breastfed
infant” ([3] p.5); the UK National Health Service (NHS)
has recently updated its recommendations for breastfeed-
ing women to restrict “intake to less than 200 mg a day”
(previously 300 mg/day) as caffeine “can make your baby
restless” and “may keep them awake” ([4] sec.6). How-
ever, the evidence behind the advice is unclear. Both a
major recent systematic review of the safety of caffeine
consumption [5] and a recent umbrella review of clinical
trials and observational studies of coffee intake and out-
comes [6] did not consider the demographic of breastfeed-
ing mothers and their infants. A further recent systematic
review on caffeine and sleep [7] highlighted studies that
found no significant effects on frequency of infant night
waking between infants of 177 mothers who were heavy
caffeine consumers (≥300 mg/day) versus infants of moth-
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ers who were low consumers during pregnancy and at 3
months postpartum [8], or on the heart rate and sleep time
in breastfed infants of mothers ingesting caffeine over five
days versus mothers ingesting no caffeine over 5 days [9].
Caffeine is a methylxanthine that acts as a central nervous
system (CNS) stimulant, and naturally occurs in several
foods. Coffee and tea account for over 90% of caffeine
consumption, and in countries where these are consumed,
average daily caffeine consumption of adults is approxi-
mately 200 mg [10]. The health effects of caffeine are fre-
quently debated, but the potential adverse effects of high
intake mean that moderate intake of ≤400 mg/day is rec-
ommended for adults [5, 6]. During pregnancy, for ex-
ample, caffeine has been associated with increased risk
of miscarriage [11] and low birth weight [12]. Caffeine
consumed by the mother passes into breastmilk, and caf-
feine has a longer half-life in infancy with even more de-
layed elimination in breastfed infants [13]. On the other
hand, caffeine is not completely contraindicated in infants.
The stimulant effects of caffeine are used clinically for the
treatment of apnoea of prematurity, which is “cessation
of breathing that lasts for more than 15 seconds…accom-
panied by hypoxia or bradycardia” ([14] p.2113). Trials
in preterm, low birthweight infants demonstrate that caf-
feine is effective and safe with fewer respiratory complica-
tions, better neurodevelopmental outcomes in early child-
hood [15, 16], and no evidence of significant longer term
complications (such as functional impairment and abnor-
malities in sleep architecture) compared with placebo [17,
18]. Side effects, such as tachycardia and increased meta-
bolic rates, may be caused by methylxanthines but caf-
feine has a better side effect profile, longer half-life, and
does not need drug level monitoring compared with oth-
er methylxanthines, and is therefore the current drug of
choice [19].
In the interests of both child health and provision of evi-
dence-based advice to breastfeeding mothers, this system-
atic review aimed to examine evidence on the effects of
maternal caffeine consumption on the breastfed infant, re-
garding both primary outcomes – impact on infant sleep-
ing behaviour, feeding behaviour, health, and developmen-
tal milestones – and secondary outcomes, namely maternal
outcomes impacting on the breastfed infant, and long term
health effects in the breastfed infant.
Methods
Protocol registration
The systematic review protocol was registered on PROS-
PERO, review registration number: CRD42017078790.
Search strategy
A joint literature search was undertaken alongside a sep-
arate review regarding exposure to maternal alcohol con-
sumption. The initial search therefore contained both caf-
feine- and alcohol-related terms, with no restriction on
publication year or language.
Online literature searches to October 2017 were performed
in the databases MEDLINE, EMBASE, Web of Science,
and CINAHL. Text words and relevant MeSH terms relat-
ed to caffeine, alcohol, and breastfeeding were combined
using Boolean logical operators (appendix 1). The same
search procedure was applied to all databases with minor
alterations where appropriate.
Retrieved references were imported to reference manage-
ment and an online systematic review platform (Covi-
dence) where they were deduplicated.
Additional studies and published review articles were
searched online in the Cochrane Library (including
Cochrane Database of Systematic Reviews), and the cata-
logue of the British Library, which covers doctoral theses,
was also searched (appendices 2 and 3). In the Cochrane
Library, terms were searched only in “Title, Abstract, Key-
words” and non-human titles were removed. Remaining
references were title and abstract screened by two review-
ers (appendices 2 and 3 contain summary tables of
Cochrane Library and British Library search results).
Hand-searching of the Journal of Human Lactation was
performed, but this was not possible for Breastfeeding Re-
view owing to a lack of subscription. Citation searching of
included studies was undertaken.
Inclusion and exclusion criteria
Study selection was performed independently by two re-
viewers based on criteria detailed in figure 1. Conflicts
were resolved by discussion between the two reviewers,
with a third reviewer consulted as necessary. Studies ex-
cluded at full text review were assigned an exclusion rea-
son by each reviewer, with conflicts again resolved
through discussion (appendix 4). Included studies were di-
vided according to topic area, with only studies concern-
ing caffeine intake included in this review. The full texts
of the remaining included studies were imported to Covi-
dence for data extraction and quality assessment.
Data extraction
The main reviewer performed data extraction on included
studies using a standardised form (appendix 5). Extracted
data were checked by the second reviewer. Information
was collected about study, mother and child characteristics
(including breastfeeding status), maternal diet, quantity
and frequency of caffeine consumed, and effects on the
breastfed child. Study outcomes were divided into primary
outcomes, where caffeine exposure via breastmilk directly
affected the child in the shorter term (impact on infant
Figure 1: Inclusion and exclusion criteria.RCT = randomised con-
trolled trials
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sleeping behaviour, feeding behaviour, infant health and
developmental milestones), and secondary outcomes in-
cluding longer-term child health effects that did not man-
ifest themselves during breastfeeding, and maternal out-
comes, for example, maternal behaviour or health
influencing extent of breastfeeding.
Risk of bias assessment
Risk of bias was assessed by two reviewers independently
using the Newcastle-Ottawa scale for cohort studies [20].
For crossover and N-of-1 studies, quality was assessed us-
ing the same scale, plus assessment of the risk of carry-
over effect, and availability of paired data for assessing
the differences within individuals, see appendix 5. Risk of
bias assessments were compared and conflicts resolved by
agreement between the two reviewers, with input of a third
reviewer as necessary.
Data synthesis and presentation
Results are presented in narrative and tabular form as there
was insufficient comparable data to perform meta-analysis.
Where data were presented only for individual participants
[9], we calculated and presented the summary statistics
(means and standard deviations) from the data.
Results
Literature search
Online searches of databases returned 2547 unique records
for title and abstract screening, of which 65 studies were
eligible for full text review (fig. 2). Five studies met the
study selection criteria and were included in the review.
Included studies
Of the five included studies, two were prospective cohort
studies, two were crossover studies, and one was an N-
of-1 trial. They were conducted between 1981 and 2011.
Though undertaken in various locations worldwide, all
were published in English. Detailed information about par-
ticipant characteristics, exposures and outcomes reported
is provided in table 1.
Excluded studies
Sixty studies were excluded at full text review. The majori-
ty of the studies were excluded on grounds of wrong expo-
sure, mainly due to maternal consumption of caffeine not
being measured during the postpartum period (versus dur-
ing pregnancy), see figure 2.
Table 1: Characteristics of included studies.
Article
Study design
Participant characteristics Exposure (maternal caffeine intake during
breastfeeding) and Control
Outcome (effect on breastfed infant)
and method of measurement
Ryu 1985 [9]
Randomised crossover tri-
al
“Twelve healthy normal white women and their normal in-
fants” from mothers who gave birth at Iowa City Hospital
between Jan–May 1983 and were planning to breast-
feed. All consumed caffeine on a regular basis (pre-preg-
nancy intake 54–877 mg/day with voluntary reduction in
consumption during pregnancy and lactation). No state-
ment on exclusivity of breastfeeding.
At onset of study, mean infant age 47.1 (SD 15.9) days,
and mean maternal age 29.2 (SD 3.5) years.
Exposure: 500 mg caffeine on 5 days, with
precise timings of intake measured on days 4
and 5 and heart-rates / sleeping time mea-
sured for 24 hours on day 5.
Control: No caffeine on 5 days, but precise
timings of placebo measured on days 4 and 5
and heart-rates / sleeping time measured for
24 hours on day 5.
Heart rate over single 24-hour period via
automatic monitor.
Sleeping time over same 24 hours via
counter and mother reporting
Santos et al. 2012 [8]
Prospective cohort study
625 breastfed infants drawing from 885 infants in a sub-
sample (born Oct–Dec 2004) of the Pelotas cohort,
which included all 4231 children born in city of Pelotas,
Brazil, in 2004. Only infants from singleton pregnancies
were included in analyses. No statement on exclusivity of
breastfeeding.
Maternal age: 171 <20 years, 626 20–35 years, 87 >35
years.
Exposure: Heavy caffeine consumption (≥300
mg/day) from coffee and/or mate at 3 months
postpartum
Control: <300 mg/day caffeine consumption
from coffee and/or mate at 3 months postpar-
tum
For subsample (n = 885), infant sleeping
pattern for the 15 days prior to 3 months
postpartum interview, mother reported.
Crying and colic at 3 months via mother
interview of entire cohort (n = 3985).
Frequent night waking at 12 months via
mother interview (n = 3907)*.
Clifford et al. 2006 [21]
Prospective cohort study
856 mothers (mean age: 29.4 (SD 4.9) years) who gave
birth at term to live singletons of birth weight appropriate
for gestational age in either of the 2 London (Ontario)
hospitals providing obstetrical services were approached
between January 15 and September 16 1999 before hos-
pital discharge. The association between maternal caf-
feine intake and continuation of FBF was explored in a
subgroup of 396 infants who were FBF at 1 week.
Maternal age of subsample: 4 <20 years, 318 20-34
years, 74 >34 years.
Exposure: Caffeine at 6 months postpartum
Control: No caffeine at 6 months postpartum
Continuation of FBF at 6 months, via
postal survey of mothers.
Evans et al. 1981 [22]
Randomised crossover tri-
al†
20 exclusively breastfed infants (12 girls and 8 boys)
aged 3–18 weeks (average 7 weeks) presenting with col-
ic initially diagnosed by family doctor or community nurse
and confirmed by paediatrician. Onset of colic at median
age 3 weeks.
All but two of infants born at 39 weeks plus gestation.
Exposure: Chocolate
Control: No chocolate in maternal diet
One or more colic symptoms via mother
reported diary over 12 day period.
Uenishi et al. 2011 [23]
N-of-1 trial
92 exclusively breastfed Japanese infants with atopic
dermatitis aged 3–8 months (average 4.8 months), suf-
fering from skin lesions for at least 2 months and fulfilling
Japanese Dermatology Association criteria for diagnosis
of atopic dermatitis.
Exposure: Chocolate or coffee challenge test
(eaten at breakfast for 2 days, volume equiv-
alent to that the mothers would have for a
meal).
Control: Initial exclusion test of chocolate/cof-
fee, and exclusion of chocolate/coffee after
positive challenge test.
Aggravation of atopic dermatitis, ob-
served by the dermatologists “before and
after” the exclusion test, and on the day
after completion of the challenge test.
FBF = full breast feeding; SD = standard deviation * Outcomes not reviewed because data unavailable. † This trial investigated the effect of maternal consumption of cow’s milk
on colic symptoms using a crossover design; maternal chocolate consumption was not restricted by this design and therefore the study was regarded as an observational cohort
study for the purpose of this review.
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Participants
The two crossover trials [9, 22] and the N-of-1 trial [23]
had small sample sizes (ranging from 12 to 92 mother-in-
fant pairs). The two other studies drew their samples from
larger cohorts: Santos et al. [8] examined the effects of ma-
ternal caffeine consumption in 625 breastfed infants from
a subsample of a population cohort of Pelotas, Brazil; Clif-
ford et al. [21] investigated 395 mothers who were still ful-
ly breastfeeding at 1 week postpartum out of a sample of
856 mothers.
Exposure
Only three of the studies reported intake of caffeine itself
[8, 9, 21], and only Ryu [9] and Santos et al. [8] specified
a quantity or threshold amount of maternal caffeine con-
sumption during breastfeeding (500 mg/day and ≥300 mg/
day respectively). The remaining two studies [22, 23] in-
vestigated consumption of specific foods, some of which
contain caffeine.
Risk of bias assessment
A summary of the risk of bias assessment is presented in
figure 3. The three most relevant studies (Ryu [9], Santos
et al. [8], and Clifford et al. [21]) were found to be of mod-
Figure 2: PRISMA flow chart for literature retrieval and study se-
lection.
erate to poor quality in the risk of bias assessment, whereas
Evans et al. [22] and Uenishi et al. [23] had still higher risk
of bias for the question of how caffeine affects the breast-
fed child. Where the effects of exposure to various foods
(rather than exposure to caffeine per se) were the focus of
the research [22, 23], the risk of bias was assessed with
respect to exposure to caffeine-containing foods (choco-
late and/or coffee in these studies) and the low scores of
these studies reflect this. There is potential risk of bias as-
sociated with incomplete outcome reporting in Santos et
al. [8], with data not provided for some investigated out-
comes (crying and colic at 3 months, and frequent night
waking at 12 months) where no significant associations
were found. The author was contacted to request data but
gave no response. The additional questions assessed for
crossover and N-of-1 studies are reported in table 2 which
shows a reasonable performance in Ryu [9] but relative-
ly high risk of bias in Uenishi et al. [23] As chocolate ex-
posure in Evans et al. was a self-reported exposure rather
than a focus of the crossover trial, the crossover questions
were not applicable to the caffeine exposure but reported
for completion.
Figure 3: Summary of risk of bias assessment based on Newcas-
tle-Ottawa Quality Assessment Scale for Cohort Studies. A filled
yellow star indicates that a star has been awarded, as outlined by
Wells et al. [18], and a blank star indicates that no star has been
awarded, and the study has been graded as poor quality in that
category.
Table 2: Summary of crossover / N-of-1 trials additional risk of bias assessment.
Study Q1 Can it be assumed that the trial was not biased from carryover ef-
fects?
Q2 Are unbiased data (paired data assessing difference within indi-
vidual participants) available?
Ryu 1989 [9] Yes. Caffeine intake was blinded and the order was randomised. Although
there was no washout period between the exposure and non-exposure period
for caffeine, testing of the infant took place on days 4 and 9 (of two blocks of
5 days) to protect against carryover effect from pre-study diet and substance
consumed during the first 5-day block.
Available but not assessed.
Evans et al. 1985
[22]
Not applicable to caffeine-related data: maternal chocolate consumption was
not investigated in a crossover design, rather it was a secondary self-reported
exposure. (Main exposure studied was cow's milk. Regarding cow’s milk,
study design attempted to exclude carryover effect by grouping trial days into
2 day blocks of either cow's or soya milk, randomly assigned, and only as-
sessing data from day 2 of each block.)
Not applicable to caffeine-related data. (Unbiased data also unavailable re-
garding main exposure studied.)
Uenishi et al. 2011
[23]
No. No explicit consideration was given to carryover effect and, apart from
the initial 2 week maternal exclusion tests, no information is given about peri-
od of time elapsed between challenge tests for different foods and rechal-
lenge tests. Only infants with a positive exclusion test underwent subsequent
challenge tests and therefore potential influence of regression to the mean
cannot be ruled out. The authors stated that acceptability for carrying out
rechallenge tests was low and that in the few rechallenge tests undertaken,
the challenge test results were reaffirmed.
Unavailable.
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Outcomes
Two papers investigated the effect of caffeine on sleep be-
haviour, as well as 24-hour heart rate [9], and crying and
colic [8], see table 3. In a small, double-blind crossover
trial, Ryu found no significant effects of short-term daily
intake of 500 mg caffeine on 24-hour infant heart rate or
24-hour infant sleep time [9]. Santos et al. found an in-
creased (but not statistically significant) prevalence ratio
(adjusted ratio 1.49, 95% confidence interval [CI]
0.89–2.51; p = 0.128) of frequent night waking amongst
breastfed infants whose mothers were heavy caffeine con-
sumers versus breastfed infants whose mothers were not
heavy caffeine consumers [8]. Crying and colic were mea-
sured by Santos et al. but the data were unavailable. Clif-
ford et al. [21] found a decreased rate of full breastfeeding
at 6 months postpartum amongst infants of mothers who
consumed caffeine (29%) versus those who abstained
(53%). Evans et al. [22] measured infant colic rates and
found significantly increased colic rates on days when
mothers consumed chocolate. Uenishi et al. [23] investi-
gated aggravation of atopic dermatitis and found that skin
lesions increased following chocolate and coffee challenge
tests in 18 instances and 7 instances, respectively, of total
107 maternal challenge tests; however, statistical signifi-
cance was not reported.
Discussion
The most prominent finding of this review is the extreme
paucity of evidence about maternal consumption of a com-
monplace stimulant during breastfeeding which could af-
fect both child and maternal health. A second significant
observation is that the studies found are of limited quality,
mostly having very small sample sizes, inadequate control
of potential confounders, and risk of bias in measuring ex-
posure and outcomes. Coupling the lack of high quality
studies with the inconsistency of the data available makes
it difficult to draw any conclusions about the effects of caf-
feine exposure during breastfeeding.
Table 3: Summary of results from included studies.
Article
Outcome type
Results and statistics Narrative summary of key study findings, strengths and limita-
tions
Ryu, 1985 [9]
Physiological
For caffeine vs no caffeine periods
• Mean 24-hr heart rate: 143.7 bpm (SD 5.1) vs 145.3 bpm (SD 5.4) (n =
11)
• Mean 24-hr sleep time as % of mean observation time:*
- Counter 60.1% (SD 9.0) vs 60.6% (SD 5.7)
- Mother recorded 57.9% (SD 9.2) vs 61.0% (SD 7.3)
• No significant difference between caffeine vs non-caffeine periods in
mean heart rate (t = 1.49, p = 0.17) and counter sleep time (t = 1.00, p =
0.34) in 9 infants with counting times >21 hrs and in sleep time recorded
by 10 mothers† (t = 1.06, p = 0.32).
No evidence of 24-hour heart rate or sleep time alteration during caf-
feine period versus no caffeine period, and no evidence of dose-relat-
ed response. Moderate level of maternal coffee consumption during
lactation appears unlikely to affect breast-fed infants after first few
weeks of life.
Key strengths and limitations: randomised cross-over study with ob-
jectively measured outcomes; small sample size; level of caffeine
consumption during pregnancy unclear; short periods of exposure
and follow-up.
Santos et al. 2012 [8]
Physiological
PR of frequent night waking (>3 times/night) among 77 breastfed only in-
fants of mothers with heavy caffeine consumption vs those of mothers
with no heavy caffeine consumption (n = 548) at 3 mo postpartum:
Crude analysis: PR 1.46 (95% CI 0.88–2.41); p = 0.138
Adjusted analysis: PR 1.49 (95% CI 0.89–2.51); p = 0.128. Controlled for
maternal age, skin colour, parity, alcohol consumption, child’s gender,
and family income.
Infants of mothers with heavy caffeine consumption at 3 mo postpar-
tum demonstrated increased PR for frequent night waking, but at a
nonsignificant level.
Also assessed effect of caffeine on child crying and colic at 3 mo
postpartum, and frequent night waking at 12 mo postpartum. Neither
crude nor adjusted analysis showed evidence of association.‡
Key strengths and limitations: participants were drawn from a
prospective population birth cohort; caffeine content of consumed
drinks objectively verified; quantity of drink consumption and infant
outcomes self-reported; analysis not controlling for caffeine consump-
tion during pregnancy. Data for some measured outcomes not report-
ed.
Clifford et al., 2006 [21]
Maternal
Of 395 mothers who were fully breastfeeding at 1 week postpartum:
Maintenance of FBF for maternal caffeine vs no caffeine consumption at
6 mo postpartum:
102/350 (29.1%) vs 24/45 (53.3%); p <0.05, chi-squared test.
Maternal caffeine consumption at 6 mo postpartum appeared to be
associated with decreased rates of FBF at 6 mo postpartum.
Key strengths and limitations: prospective cohort study; infant out-
comes not examined, self-reported caffeine consumption and out-
come (FBF); univariate analysis not adjusting for potential con-
founders.
Evans et al. 1981§ [22]
Clinical
For 20 mother-infant pairs:
Infants with colic symptoms on days when exposed to chocolate vs days
when not exposed: 80.4% (34/42) vs 63.6% (126/198); p <0.05
Significantly increased infant colic rates on days when breastfeeding
mother consumed chocolate.
Key strengths and limitations: disease-specific cohort (infants with
persistent colic); small sample size; association could be attributed to
ingredients other than caffeine; self-reported exposure and infant out-
come; univariate analysis not adjusting for potential confounders.
Uenishi et al. 2011§ [23]
Clinical
Atopic dermatitis lesions:
Of 92 mother-infant pairs who undertook a preliminary 2 week exclusion
test of all tested foods (both tree-nut related, and fermented foods), 67 in-
fants (73%) showed positive response (great or fair improvement in skin
lesions), and underwent challenge tests where each food was reintro-
duced in succession for two days at a time, and the lesions assessed.
The 67 infants responded positively to a total of 107 maternal challenges
(tree-nut related and fermented foods), 1–4 positive results each (1.6 av-
erage):
– severely exacerbated: 43 infants
– moderately exacerbated: 64 infants
Chocolate challenge test positive in 18/67 infants.
Coffee challenge test positive in 7/67 infants.
Exposure to caffeine via a challenge test with caffeine-containing
food. Of all the foods tested, chocolate was a predominant challenge
test-positive food: 18 of 107 maternal challenges (third most common
after soy sauce[n = 26] and yogurt [n = 19]). Coffee consumption re-
sulted in positive challenge tests in 7 instances. Statistical signifi-
cance was not reported.
Key strengths and limitations: disease-specific cohort (infants with
atopic dermatitis); association could be attributed to ingredients other
than caffeine; assessment of exposure and outcome not blinded; dis-
crepant challenge tests between chocolate and coffee suggests that
caffeine may not be the causal allergen.
FBF = full breast feeding; PR = prevalence ratio; SD = standard deviation * Counter time was derived from record of electronic heart beat counting device, which estimated sleep
time based on heart rate dropping below a heart rate associated with sleep in each infant (predetermined at about 30% lower than the individual’s heart rate when awake and
quiet). During the same period, mothers also recorded infant sleep time. † Mother of one infant failed to record sleep time. ‡ Numerical results for these outcomes (crying and
colic at 3 mo; frequent night waking at 12 mo) were not reported. § Caffeine per se not investigated, rather maternal intake of certain foods, in some of which caffeine occurs.
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In Wikoff and colleagues’ 2017 systematic review regard-
ing caffeine safety [5], studies where attempts were made
to quantify caffeine exposure, for example by sample
analysis, rather than relying on self-report of exposure,
were considered to “better inform the body of evidence”
([5] p. 631). Of the five included studies, Ryu [9] and San-
tos et al. [8] attempted to do this, making these studies po-
tentially more informative than those that were not specif-
ic about the quantity of caffeine consumed. Clifford et al.
[21] specified caffeine or no caffeine which at least pro-
vides a clear threshold for exposure. Evans et al. [22] and
Uenishi et al. [23] did not measure caffeine.
The different approaches to measuring caffeine exposure
and outcomes also affect the reliability of the outcomes re-
ported. Studies relying on mothers’ self-reports of infant
night waking [8, 9] could be influenced by mothers them-
selves experiencing the CNS stimulant effects of heavy
caffeine consumption and being more easily awakened
from sleep than mothers drinking less or no caffeine. This
issue can be overcome by providing additional, objective
measures of the sleep-related outcomes, e.g., by reporting
an estimated sleep time based on a heart rate counter as
adopted in the Ryu study [9]. However, the increased tech-
nical requirement may restrict such studies to small sample
sizes, which may limit generalisability.
Study design poses a challenge for investigating effects
of maternal caffeine intake on the breastfed infant. A ran-
domised crossover design has the advantage of avoiding
problems with case-control parity and therefore overcomes
the issue of unmeasured confounding in observational
studies. Carryover effect is the major potential threat for
studies of such design, although none of the included stud-
ies tested for this effect.
The disparity in directness of exposure between the studies
presents difficulty in comparing and interpreting their re-
sults. Evans et al. [22] and Uenishi et al. [23] did not inves-
tigate caffeine per se, but rather the consumption of foods
incidentally containing caffeine. These studies were never-
theless included because they documented outcomes in in-
fants relating to foods that contain caffeine. However, the
indirect focus reduces the relevance and reliability of the
results. It is unclear whether caffeine is the causal ingredi-
ent, as the observed effects may be associated with anoth-
er substance in the food. Indeed, results related to choco-
late consumption appear to have been more pronounced in
these studies, and the different rate of aggravation of atopic
dermatitis in response to coffee and chocolate [23] at least
suggests that caffeine was not the sole aggravating sub-
stance.
Finally, a crucial issue in assessing the effects of maternal
caffeine consumption during breastfeeding on the breast-
fed child is the control of potential confounders, which are
factors independently associated with both maternal caf-
feine consumption and the infant/maternal outcomes of in-
terest. Failure to take into account these confounders may
result in under- or over-estimation of the true effect of ma-
ternal caffeine consumption during breastfeeding. Poten-
tially important confounders include various demographic
and socioeconomic factors such as maternal age, co-mor-
bidity, education, income, smoking, family support, and
so forth. One potential confounder worth highlighting is
maternal caffeine consumption during pregnancy. On the
one hand, caffeine consumption during pregnancy may
be closely associated with caffeine consumption during
breastfeeding through common socioeconomic risk factors
mentioned above (although they could represent two dis-
parate decisions that the mother could make). On the other
hand, regular caffeine exposure in utero could have direct
effects on the fetus, potentially leading to an infant devel-
oping “tolerance” to caffeine [24] and hence attenuating
the effects of maternal consumption of caffeine during
breastfeeding. These complicated relationships were not
adequately investigated in the studies included in this re-
view and it is important that future studies explore the im-
portance and evaluate the impact of controlling for these
confounding variables.
Strengths and limitations
Strengths of this review were the comprehensive search us-
ing broadly defined keywords to capture as many poten-
tially relevant references as possible, careful appraisal of
the included studies, and an organised and well-document-
ed screening process facilitated by the Covidence software.
Limitations included the inaccessibility of a potentially rel-
evant reference source for hand search (Breastfeeding Re-
view journal, although this journal was covered in the on-
line databases with abstracts) and, on the other hand, the
issue of titles and keywords not always being indicative
of article relevance when hand-searching elsewhere. Al-
though only studies published in English language were
included because of resource constraints, we intentionally
did not apply language restrictions in our searches. No
non-English language articles that would have otherwise
met the inclusion criteria were found. Nevertheless, as we
only used English terms when carrying out the searches,
there remains a small risk of language bias due to non-
identification of articles that have not been indexed in Eng-
lish language. In addition, due to the small number of stud-
ies identified and diversity of outcome measures that they
reported, we could not carry out meta-analyses and were
unable to assess potential publication bias (or small study
effects) using funnel plots. A further major limitation of
the review relates to the lack of high quality evidence (i.e.,
from randomised or quasi-randomised parallel group tri-
als) that is currently available, which prevents us from
drawing any firm conclusions.
Future work
Further research on the effects of maternal consumption of
caffeine on the breastfed child is warranted. The included
studies appear to be directed more toward investigation of
potentially negative health impacts given the existing asso-
ciation between heavy caffeine consumption in pregnancy
and negative fetal outcomes [5, 6, 11, 12]; future research
should potentially address more diverse outcomes specifi-
cally for maternal caffeine consumption during breastfeed-
ing on the breastfed child, considering positive as well as
negative implications for the health of both the mother and
the infant, and thus reducing the risk of confirmation bias.
On the other hand, although the clinical use of caffeine in
neonates appears to have a relatively good safety profile,
the potential effects of caffeine on breastfed infants (e.g.,
on weight gain) related to its diuretic and calcium excre-
tion effects may require further confirmation. Most effec-
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tively, research could take the form of large birth cohort
studies investigating direct effects on child health and be-
havioural outcomes, alongside maternal outcomes such as
extent of breastfeeding (exclusivity and duration), and po-
tentially other more indirect maternal outcomes such as
anxiety and fatigue which may also affect the breastfed in-
fant. Furthermore, given the safety profile of clinical use
of caffeine in neonates and lack of serious adverse effects
observed in the limited research to date, randomised con-
trolled trials investigating the effect on the breastfed infant
of moderate maternal caffeine consumption (for example,
within current NHS guidelines for breastfeeding mothers)
versus no caffeine consumption could potentially be ac-
ceptable and provide the most reliable evidence.
Also of interest are the pronounced effects on colic rates
[22] and atopic dermatitis lesions [23] that were found
in relation to maternal chocolate consumption, suggesting
that further research into maternal chocolate exposure on
the breastfed infant could be useful in informing dietary
advice for breastfeeding mothers.
Conclusion
To our knowledge, this is the first systematic review of
evidence on the effects of maternal caffeine consumption
during breastfeeding on the breastfed child. Considering
the prevalence of caffeine consumption in our society, it is
surprising that there are so few published studies, mostly
of small sample sizes and moderate to poor quality. With
a view to both child health and providing evidence-based
dietary advice to breastfeeding mothers, further research
should be conducted into the potential positive and neg-
ative effects of moderate maternal caffeine consumption
during breastfeeding on the breastfed child.
Appendix 1‒ 5
The appendices are available as separate files for down-
loading at https://smw.ch/en/article/doi/smw.2018.14665/
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